We arehappy to highlight some of the clinical trials that have been held with lowdoses of NTX (LDN). With LDN being ageneric drug, it does not have the financial support of other pharmaceuticaldrugs and therefore the clinical trials to-date have been small. That being said, all clinical trials to-datesupport the need for larger scale trials.Please see the attached link for moreinformation. We will continue to update this page as more trials get published.
Dr Mackay MD, PhD (Stanford) talking about Fibromyalgia (fast forward to 45mins 42 seconds)
“The preliminary evidence continues to show that low-dose naltrexone has a specific and clinically beneficial impact on fibromyalgia pain. Our clinical studies showed 1/3 response rate showing significant improvement in pain, fatigue and sleep. When we used only the criteria of significant reduction of pain 65% are responders with 50% of the patients feeling much improved after their LDN treatment. LDN is widely available, inexpensive, safe, and well-tolerated.”
Dr. David A. McLain, MD, FACP, FACR, McLain Medical Associates, Birmingham, AL
